Option Care and BioScrip Complete Merger

BANNOCKBURN, Ill. and DENVER (August 7, 2019)—Option Care Enterprises, Inc. (Option Care) and BioScrip, Inc. (BioScrip) announced the successful completion of a merger, which follows the satisfaction of the transaction’s closing conditions, including approval by BioScrip shareholders and the receipt of all necessary regulatory approvals.

The newly combined company, Option Care Health, Inc. (Option Care Health or the company), emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

John Rademacher, CEO of Option Care Health, said, “Today marks the beginning of an exciting new chapter as we unite two strong organizations with proud histories as market leaders. This combination enables us to reimagine the infusion care experience to unleash the full potential of high-quality care in a lower cost setting on a national scale. We are now the only independent provider focused on delivering a full spectrum of infusion therapies to patients across the country. Our deep clinical expertise, broad therapy portfolio and enhanced financial profile empower us to deliver superior outcomes and set the standard for patient care.”

Option Care Health will continue to focus on:

• Patient-centered care model, providing deeply personalized care to patients in all 50 states, supported by the broadest commercial and clinical coverage with a unique product offering.
• Clinical and market leadership, leveraging best-in-class clinical team to consistently raise quality standards and patient outcomes while collaborating with health systems, payers and manufacturers to broaden the therapy portfolio and clinical reach.
• Investing in people, technology and operations to drive profitable growth, while setting the industry standard for infusion services.

Daniel E. Greenleaf, former CEO of BioScrip, commented, “I’m proud of the BioScrip team and the care that we delivered every day to patients who trusted us to provide extraordinary care. This new enterprise combines two independent market leaders and enables the organization to truly redefine infusion therapy in the alternate site setting. With a significantly improved capital structure and financial profile, I’m confident Option Care Health will continue to build upon the momentum of BioScrip and Option Care.”

Option Care Health will be headquartered in Bannockburn, Illinois and led by Rademacher as CEO and Mike Shapiro as chief financial officer. Harry Kraemer, former chairman and chief executive officer of Baxter International Inc., will serve as chairman of the Board of Option Care Health.

In connection with the transaction, Jefferies LLC and Moelis & Company LLC acted as joint financial advisors to BioScrip, and Gibson, Dunn & Crutcher LLP served as legal advisor. Goldman Sachs & Co. LLC and BofA Merrill Lynch acted as financial advisors and Kirkland & Ellis LLP acted as legal advisor to Option Care.

Visit optioncarehealth.com for more information.